Oncology Institute (NASDAQ:STLN) Given New $8.00 Price Target at Lake Street Capital

Oncology Institute (NASDAQ:STLN) had its price objective cut by Lake Street Capital from $10.00 to $8.00 in a research note issued to investors on Friday,Benzinga reports. They currently have a buy rating on the stock.

STLN has been the subject of several other reports. B. Riley Financial restated a “buy” rating and issued a $10.00 target price (down from $11.00) on shares of Oncology Institute in a research note on Friday. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Oncology Institute in a report on Tuesday, November 3rd. Needham & Company LLC upped their price target on Oncology Institute from $7.00 to $9.00 and gave the stock a “buy” rating in a research report on Wednesday, October 14th. Finally, BTIG Research upped their price target on Oncology Institute from $9.00 to $10.00 and gave the stock a “buy” rating in a research report on Friday. Four equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $9.25.

Oncology Institute Price Performance

NASDAQ:STLN opened at $3.62 on Friday. Oncology Institute has a fifty-two week low of $2.32 and a fifty-two week high of $7.13. The company has a market cap of $357.80 million, a PE ratio of -12.48 and a beta of 0.44. The firm has a 50-day moving average price of $6.43.

Oncology Institute (NASDAQ:STLN) last posted its quarterly earnings data on Thursday, November 5th. The company reported ($0.13) EPS for the quarter, missing the consensus estimate of ($0.07) by ($0.06). The company had revenue of $169.77 million for the quarter. Equities analysts expect that Oncology Institute will post -0.21 earnings per share for the current fiscal year.

Insider Activity

In other Oncology Institute news, major shareholder Jorey Chernett purchased 12,000 shares of the stock in a transaction on Friday, August 14th. The stock was acquired at an average price of $6.54 per share, with a total value of $78,480.00. Following the completion of the acquisition, the insider owned 10,660,858 shares in the company, valued at $69,722,011.32. The trade was a 0.11% increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which can be accessed through this link. Also, Director Brad Hively sold 298,853 shares of the business’s stock in a transaction dated Friday, August 21st. The stock was sold at an average price of $6.51, for a total value of $1,945,533.03. Following the sale, the director owned 411,976 shares in the company, valued at $2,681,963.76. The trade was a 42.04% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 4.40% of the stock is currently owned by company insiders.

Institutional Trading of Oncology Institute

Institutional investors have recently bought and sold shares of the stock. Legal & General Group Plc purchased a new stake in shares of Oncology Institute during the second quarter valued at $41,000. AMG National Trust Bank acquired a new position in shares of Oncology Institute in the 2nd quarter valued at $54,000. Engineers Gate Manager LP acquired a new position in shares of Oncology Institute in the 2nd quarter valued at $67,000. Fermata Advisors LLC purchased a new position in Oncology Institute in the 2nd quarter worth $70,000. Finally, WINTON GROUP Ltd purchased a new position in Oncology Institute in the 2nd quarter worth $102,000. 36.86% of the stock is currently owned by institutional investors and hedge funds.

Oncology Institute Company Profile

The Oncology Institute is a value-based oncology care company focused on delivering comprehensive cancer treatment and related services through community-based care settings. Its model is designed to support patients throughout the cancer-care journey while coordinating treatment among oncologists, primary-care providers, specialists and other healthcare professionals.

The company provides medical oncology and hematology services, cancer screening and diagnosis, treatment planning, chemotherapy and other infusion therapies, supportive care, survivorship services and care-management programs.